Abstract:Background: Information regarding antibody response to COVID-19 vaccines in cancer patients undergoing therapy is needed for vaccine recommendations and timing of additional doses. This longitudinal study evaluates anti-RBD and neutralizing antibody (NAb) response to COVID-19 vaccines in patients on treatment and post stem cell transplant (SCT).Methods: For mRNA vaccines, anti-RBD and NAb were assessed before vaccination (T0), prior to 2nd dose (T1), 1 month after the 2nd dose (T2), and 3 months after the 2nd dose (T3). For J&J, T1 was 1 month, T2, 2 months and T3, 4 months after vaccine. Primary objective was GMTs of anti-RDB and NAb (%) at above timepoints. Other objectives were a) proportion of patients with anti-RBD ≥100 U/mL, b) correlation between anti-RBD and NAb, c) antibody responses of the 2 mRNA vaccines, and d) anti-RBD in breakthrough COVID-19 cases.Findings: Between 3/2/2021 and 7/30/2021, 438 cancer patients were enrolled. 108 (25%) were post-SCT and 330 (75%) on treatment: 176 (40%) on chemotherapy (C), 21 (5%) on chemoimmunotherapy (C+I), 72 (19%) on immunotherapy (I), and 58 (13%) on targeted oral agents (TOA). 60 % received Pfizer, 36 % Moderna, and 4% J&J. 11·82% of patients had anti-RBD ≥100 U/mL at T0, 25·15% at T1, 75·44 % at T2, and 81·38% at T3. At T3, 84·91% of patients on C, 81·89% on C+I, 86·67% on I, 78·18% post-SCT, and 77·50% on TOA had anti-RBD ≥ 100 U/mL. GMTs were 1·59 at T0, 12·91 at T1, 480·8 at T2 and 439·1 at T3. Neutralization (≥30%) was observed in 14·71%, 38·89%, 80·56% and 81·33% of patients at T0, T1, T2, and T3. There was no difference between the mRNA vaccines. Five patients had breakthrough infection. Four with anti-RBD available had pre-infection anti-RBD <100 U/mL. Interpretation: Four months after SARS-CoV-2 vaccination, ~ 80% of patients on cancer therapy or post-SCT have anti-RBD ≥100 U/mL and ≥30% NAb. Anti-RBD ≥100 U/mL predicts virus neutralization with accuracy. In regions with limited vaccine availability/hesitancy, antibody testing can identify 20% of the patients with relatively low titres for booster prioritization..Funding Information: This work was supported in part by the University of Kansas Cancer Centre and the Investigator Initiated Steering Committee, a grant from the NIGMS (P20 GM130423), and The University of Kansas Cancer Centre Support Grant from the NCI (P30 CA168524). A.K.G. is the Chancellors Distinguished Chair in Biomedical Sciences Endowed. Declaration of Interests: AKG and ZYP are co-founders of Sinochips Diagnostics;PS serves as advisory board member and consultant to Merck, Novartis, Exact Sciences, Seattle Genetics, Immunomedics, Myriad Genetics, AstraZeneca, Puma Biotechnology;JZ served as a scientific advisor/consultant for AstraZeneca, Biodesix, Novocure, Bayer, Daiichi Sankyo, Mirati, Novartis, Cardinal Health, Bristol Myers Squibb, Nexus Health and Sanofi and is on the speakers’ bureau for AstraZeneca and MJH Life Sciences and has received research funding from AstraZeneca, Biodesix, Novartis, Genentech/Roche, Mirati, AbbVie and Hengrui Therapeutics;GCD serves on an advisory board for Novartis;JPM serves as advisory board member and consultant to Novartis, Kite Pharmaceuticals, BMS and Allovir;RAR received institutional support from Bayer, NuCana, Incyte, AstraZeneca, Eureka therapeutics, Merck, Pfizer, and owns stock in Seattle Genetics, Actinium Pharmaceuticals Inc.;MH received consulting fees from Janssen, Pharmacyclics, Novartis Inc., Kite Pharmaceuticals and TG therapeutics. The remaining authors declare no competing interests.Ethics Approval Statement: This study was approved by the Institutional Review Board of the University of Kansas Medical Centre.

Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer

Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections

Cancer Therapy and Immunogenicity of COVID Vaccine – CANINE Study

Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

Immune responses and reinfection of SARS‐CoV‐2 Omicron variant in patients with lung cancer

Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant

Case report: Understanding the impact of persistent tissue-localization of SARS-CoV-2 on immune response activity via spatial transcriptomic analysis of two cancer patients with COVID-19 co-morbidity

Lung Cancer Models Reveal SARS-CoV-2-induced EMT Contributes to COVID-19 Pathophysiology

mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer

Immune Response and Effects of COVID-19 Vaccination in Patients with Lung Cancer—COVID Lung Vaccine Study

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multi-Center Study During the COVID-19 Outbreak

Survival and safety analysis of COVID‐19 vaccine in Chinese patients with non‐small cell lung cancer

Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients

Longitudinal Assessment of Solid Organ Transplant Recipients with SARS-CoV-2 Infection

A therapy for suppressing canonical and noncanonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response

Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations

Detection of anti-nucleocapsid antibodies associated with primary SARS-CoV-2 infection in unvaccinated and vaccinated blood donors

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

High Expression of ACE2 and TMPRSS2 at the Resection Margin Makes Lung Cancer Survivors Susceptible to SARS-CoV-2 With Unfavorable Prognosis

Impact of SARS-CoV-2 infection on immune cell cuproptosis in patients with lung adenocarcinoma via glutamine regulation